Search results
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer
Morningstar· 6 days agoSquibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its blockbuster cancer drug& ...
Yervoy cost 2024: Coupons and more
Medical News Today· 16 hours agoYervoy (ipilimumab) is a brand-name solution for intravenous injection. It’s prescribed for certain types of cancer, including melanoma, kidney cancer,...
Bristol Myers posts quarterly loss, lays out $1.5 billion cost-saving plan
Reuters via AOL· 7 days ago(Reuters) -Bristol Myers Squibb reported a first-quarter loss on Thursday as charges related to its...
Exeliom to focus on gastric cancer landscape with immune modulating drug
Clinical Trials Arena via Yahoo Finance· 6 days agoThe company will be running three trials with EXL01, but the...in the treatment arm will receive...
Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss
Morningstar· 7 days agoBy Rob Curran Bristol-Myers Squibb cut its 2024 earnings projection even as the drug giant posted a narrower-than-anticipated first-quarter loss, reflecting the impact of ...
Japan's Ono Pharma to buy U.S. drugmaker Deciphera for $2.4bn
Nikkei Asian Review· 1 day agoCompany seeks new revenue as patent expirations loom on cash-cow product
Japan's Ono Pharma says $2.4 billion Deciphera purchase 'first step' for global expansion
Reuters via AOL· 2 days agoOno Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.
Bristol Myers posts quarterly loss, revenue rises 5%
WSAU Wausau· 7 days agoBy Deena Beasley (Reuters) - Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics ...
Pipeline Moves: Investigator-led trial of Lilly’s merestinib in solid tumours terminated
Clinical Trials Arena via Yahoo Finance· 3 days agoThe drug’s PTSR decreased by 11 points to 34% in bile duct cancer, 10 points to 35% in gallbladder ...
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Zacks via Yahoo Finance· 7 days agoBristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus...
